Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2009 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (143)	1/23/2009 7:18:33 PM
From: The Dodgy Ticker	Respond to of 418

Congratulations, Enzyme and Bulba, for taking over the 1 and 2 slots in the contest. Nevertheless, I'll be back!* *..........Maybe :-)

To: BulbaMan who wrote (143)	1/28/2009 3:47:05 AM
From: dr.praveen	1 Recommendation Respond to of 418

A little munch NitroMed Announces Agreement to Be Acquired by Deerfield Management; Terminates Agreements With Archemix Corp. and JHP Pharmaceuticals, LLC LEXINGTON, MA--(MARKET WIRE)--Jan 27, 2009 -- NitroMed, Inc. (NasdaqGM:NTMD - News) today announced that it entered into a merger agreement to be acquired by affiliates of Deerfield Management, a leading healthcare investment organization. Under the terms of the merger agreement with Deerfield, NitroMed stockholders will receive $.80 per share in cash, subject to adjustment for net cash balances at the closing of the merger. Prior to entering into the merger agreement with Deerfield, NitroMed terminated its previously announced purchase and sale agreement with JHP Pharmaceuticals, LLC and its previously announced merger agreement with Archemix Corp. in accordance with the terms of those agreements, including the payment of termination fees. In connection with the termination of the JHP purchase and sale agreement, NitroMed paid a fee of approximately $900,000 to JHP; and in connection with the termination of the Archemix merger agreement, NitroMed paid a $1.5 million fee to Archemix. NitroMed entered into the merger agreement with Deerfield following the recommendation and approval of a special committee of the board of directors and the full board of directors, which both determined that the terms and conditions of the merger agreement with Deerfield was superior to the terms of both the JHP purchase and sale agreement and the Archemix merger agreement. The transaction is expected to be completed by April 2009. The merger agreement includes a "go-shop" provision that allows NitroMed, acting under the direction of a special committee of the board of directors, to solicit, negotiate and evaluate competing acquisition proposals during a post-signing period ending on February 26, 2009. In accordance with the merger agreement, NitroMed, with the assistance of its advisors, intends to actively solicit competing acquisition proposals during this period. There is no assurance that the "go-shop" provision will result in a higher offer. The closing of the proposed merger is subject to various conditions, including approval by NitroMed's stockholders and other customary closing conditions. A special meeting of NitroMed's stockholders will be scheduled as soon as practicable following the preparation and filing of proxy materials with the Securities and Exchange Commission. In connection with the termination of the JHP purchase and sale agreement, NitroMed cancelled its special meeting of stockholders to approve the sale of substantially all of NitroMed's assets to JHP. Cowen and Company, LLC is acting as exclusive financial advisor to NitroMed and Wilmer Cutler Pickering Hale and Dorr LLP is acting as legal counsel to NitroMed.

To: BulbaMan who wrote (143)	1/30/2009 5:36:50 PM
From: BulbaMan	Read Replies (3) \| Respond to of 418

1/30/09 update Stocks were unable to follow up on Wednesday's rally and Wall Street had little to show for a week's worth of trading. They had even less to show for the month, with the S&P 500's drop of -8.6% being the worst January performance on record. At Friday's close, the Nasdaq Composite Index was down -6.06% CYTD, or "Contest Year To Date" (vs. down -6.00% CYTD a week ago). However, the Nasdaq Biotech Index actually advanced a bit for the week, closing up 2.06% CYTD (vs. down -1.32% CYTD a week ago). The Contest median also had an Ok week, closing up .58% CYTD (vs. down -3.08% CYTD a week ago). ENZYME's portfolio held on to first place, closing the week up 16.35% CYTD. SCARAM's portfolio beat out my own for second place with an 11.62 % CYTD gain. At Friday's close, 17 of the 32 Contest portfolios were in the black and 13 of the 32 beat the NBI. Enjoy the weekend folks! Below is the Top Ten list on 1/30/09: 1/30/09 Rank Name Profit/Loss 1 ENZYME 16,352 2 SCARAM 11,627 3 BULBA 10,797 4 GEORGIA 7,573 5 GHMM 7,058 6 STEVEL 7,017 7 THEOX 5,837 8 RKRW 5,228 9 FILO 4,725 10 ROBERT 4,626 (All corrections, especially adjustments for splits, greatly appreciated.)